BioStock: Chordate Medical reports Q3 and carries out rights issue

Medtech company Chordate Medical has published the report for the third quarter where they particularly highlight the completion of the migraine study. Strengthened by the results of the study, the company focuses on marketing and sales in selected markets to increase market shares for a future exit. To secure financing for the activities and accelerate towards an exit, the company has decided to carry out a rights issue of approximately 51.3 MSEK. CEO Anders Weilandt comments on the capital raise and the third quarter in an interview.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/11/chordate-medical-reports-q3-and-carries-out-rights-issue/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se